Incyte Corp (OQ:INCY)
Business Focus: Biopharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 1801 Augustine Cut-Off WILMINGTON DE 19803 |
| Tel: | 1-302-2744773 |
| Website: | https://www.incyte.com |
| IR: | See website |
| Key People | ||
| Herve Hoppenot Chairman of the Board, President, Chief Executive Officer | Christiana Stamoulis Chief Financial Officer, Executive Vice President | Dashyant Dhanak Executive Vice President, Chief Scientific Officer |
| Jonathan Elliot Dickinson Executive Vice President, General Manager, Europe | Paula J. Swain Executive Vice President - Human Resources | Barry P. Flannelly Executive Vice President, General Manager, North America |
| Vijay Iyengar Executive Vice President - Global Strategy and Corporate Development | Michael James Morrissey Executive Vice President, Head of Global Technical Operations | Steven H. Stein Executive Vice President, Chief Medical Officer |
| Business Overview |
| Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Incyte Corp revenues increased 9% to $3.7B. Net income increased 75% to $597.6M. Revenues reflect OPZELURA revenues segment increase from $128.7M to $337.9M, JAKAFI revenues segment increase of 8% to $2.59B. Net income benefited from Other income (expense), net increase from $39.9M to $172.3M (income), Unrealized gain (loss) on long term inve increase from $87.6M (expense) to $43.9M (income). |
| Employees: | 2,524 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $8,214M as of Dec 31, 2023 |
| Annual revenue (TTM): | $3,696M as of Dec 31, 2023 |
| EBITDA (TTM): | $734.43M as of Dec 31, 2023 |
| Net annual income (TTM): | $597.60M as of Dec 31, 2023 |
| Free cash flow (TTM): | $464.00M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 224,526,128 as of Feb 6, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.